Literature DB >> 17942890

The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1.

Diana E Jaalouk1, Michael G Ozawa, Jessica Sun, Johanna Lahdenranta, Reinier O Schlingemann, Renata Pasqualini, Wadih Arap.   

Abstract

For two decades, the antigen recognized by the Pathologische Anatomie Leiden-Endothelium (PAL-E) monoclonal antibody, a standard vascular endothelial cell marker, has remained elusive. Here, we used a combinatorial phage display-based approach ("epitope mapping") to select peptides binding to the original PAL-E antibody. We found that a subset of the selected panel of peptides had motifs with strong homology to an exposed site within the b1 domain of human neuropilin-1 (NRP-1). We confirmed peptide binding by ELISA and by surface plasmon resonance. We also showed that the PAL-E antigen colocalizes with NRP-1 staining in endothelial cells. Crystal structure of the b1 domain in NRP-1 suggests that the PAL-E binding site overlaps with a vascular endothelial growth factor (VEGF) binding site. Taken together, these results indicate that NRP-1 is an endothelial cell antigen recognized by the true PAL-E antibody. The consistent biochemical, morphologic, and functional features between the PAL-E antigen and NRP-1 support our interpretation. Given that NRP-1 is a VEGF receptor, these results explain the attributes of the PAL-E antibody as a marker of vascular permeability and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942890     DOI: 10.1158/0008-5472.CAN-07-2737

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Maturation of the fetal human choriocapillaris.

Authors:  Takayuki Baba; Rhonda Grebe; Takuya Hasegawa; Imran Bhutto; Carol Merges; D Scott McLeod; Gerard A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

2.  From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.

Authors:  Marina Cardó-Vila; Ricardo J Giordano; Richard L Sidman; Lawrence F Bronk; Zhen Fan; John Mendelsohn; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-26       Impact factor: 11.205

Review 3.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

4.  Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.

Authors:  Adrien Bosseboeuf; Delphine Feron; Anne Tallet; Cédric Rossi; Cathy Charlier; Laurent Garderet; Denis Caillot; Philippe Moreau; Marina Cardó-Vila; Renata Pasqualini; Wadih Arap; Alfreda Destea Nelson; Bridget S Wilson; Hélène Perreault; Eric Piver; Pierre Weigel; François Girodon; Jean Harb; Edith Bigot-Corbel; Sylvie Hermouet
Journal:  JCI Insight       Date:  2017-10-05

Review 5.  The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema.

Authors:  Esmeralda K Bosma; Cornelis J F van Noorden; Reinier O Schlingemann; Ingeborg Klaassen
Journal:  Fluids Barriers CNS       Date:  2018-09-20

Review 6.  Role of anti-vimentin antibodies in allograft rejection.

Authors:  Marlene L Rose
Journal:  Hum Immunol       Date:  2013-06-15       Impact factor: 2.850

7.  Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding.

Authors:  Maria V Gelfand; Nellwyn Hagan; Aleksandra Tata; Won-Jong Oh; Baptiste Lacoste; Kyu-Tae Kang; Justyna Kopycinska; Joyce Bischoff; Jia-Huai Wang; Chenghua Gu
Journal:  Elife       Date:  2014-09-22       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.